TY - JOUR
T1 - TMEM16A-inhibitor loaded pH-responsive nanoparticles
T2 - A novel dual-targeting antitumor therapy for lung adenocarcinoma
AU - Guo, Shuai
AU - Qiu, Liang
AU - Chen, Yafei
AU - Wang, Xuzhao
AU - Ma, Biao
AU - Qu, Chang
AU - Cui, Jianmin
AU - Zhang, Hailin
AU - Xing, Chengfen
AU - Zhan, Yong
AU - An, Hailong
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China (Grant No. 11735006 to Y Zhan, 81830061 to HL An), the Natural Science Foundation of Tianjin of China (Grant No. 19JCYBJC28300 to HL An), the Natural Science Foundation of Hebei Province of China (Grant No. C2018202302 to YF Chen), the Youth Talent Support Program of Hebei Province of China (Grant No. 2013001 to YF Chen).
Funding Information:
This work was supported by the National Natural Science Foundation of China (Grant No. 11735006 to Y Zhan, 81830061 to HL An), the Natural Science Foundation of Tianjin of China (Grant No. 19JCYBJC28300 to HL An), the Natural Science Foundation of Hebei Province of China (Grant No. C2018202302 to YF Chen), the Youth Talent Support Program of Hebei Province of China (Grant No.2013001 to YF Chen).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/8
Y1 - 2020/8
N2 - To overcome the adverse effects of conventional chemotherapy for cancers, various nanoparticles based drug delivery systems have been developed. However, nanoparticles delivering drugs directly to kill tumor cells still faced with challenges, because tumors possessed adopt complex mechanism to resist damages, which compromised the therapeutic efficacy. TMEM16A/CaCCs (Calcium activates chloride channels) has been identified to be overexpressed in lung adenocarcinoma which can serve as a novel tumor specific drug target in our previous work. Here, we developed a novel dual-targeted antitumor strategy via designing a novel nano-assembled, pH-sensitive drug-delivery system loading with specific inhibitors of TMEM16A against lung adenocarcinoma. For validation, we assayed the novel dual-targeting therapy on xenograft mouse model which exhibited significant antitumor activity and not affect mouse body weight. The dual targeting therapy accomplished in this study will shed light on the development of advanced antitumor strategy.
AB - To overcome the adverse effects of conventional chemotherapy for cancers, various nanoparticles based drug delivery systems have been developed. However, nanoparticles delivering drugs directly to kill tumor cells still faced with challenges, because tumors possessed adopt complex mechanism to resist damages, which compromised the therapeutic efficacy. TMEM16A/CaCCs (Calcium activates chloride channels) has been identified to be overexpressed in lung adenocarcinoma which can serve as a novel tumor specific drug target in our previous work. Here, we developed a novel dual-targeted antitumor strategy via designing a novel nano-assembled, pH-sensitive drug-delivery system loading with specific inhibitors of TMEM16A against lung adenocarcinoma. For validation, we assayed the novel dual-targeting therapy on xenograft mouse model which exhibited significant antitumor activity and not affect mouse body weight. The dual targeting therapy accomplished in this study will shed light on the development of advanced antitumor strategy.
KW - Dual-targeting antitumor strategy
KW - Ion channel
KW - Lung adenocarcinoma
KW - pH-responsive nanocarriers
KW - TMEM16A
UR - http://www.scopus.com/inward/record.url?scp=85086580672&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2020.114062
DO - 10.1016/j.bcp.2020.114062
M3 - Article
C2 - 32492446
AN - SCOPUS:85086580672
SN - 0006-2952
VL - 178
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
M1 - 114062
ER -